The main goal of the late research of Novartis acromegaly

Source: China Council for the promotion of medicine 2012-05-07 (Reuters) - Novartis International said on Monday that its new sustained-release drug, pasireotide LAR, is more effective than the current standard treatment for acromegaly The study reached a common end point According to Swiss pharmacists, pasireotide lar induces adequate biochemical control compared to Sandostatin LAR's standard therapy Acromegaly is caused by excessive growth hormone It is characterized by hypertrophy of hands, feet and internal organs as well as changes in facial structure Sandostatin LAR is a long-term injection of octreotide acetate Named pasport acromegaly, this study is a randomized, double-blind, phase III clinical study to evaluate the efficacy and safety of pasireotide lar compared with octreotide LAR 385 patients with active acromegaly were enrolled in this study HERV é hoppenot, President of cancer Department of Novartis, said: "the positive results of phase III study show that pasireotide lar has therapeutic effect on acromegaly patients with treatment demand These results are good news for our efforts to continue our research and find new therapies for patients with pituitary related diseases Original link: http://